Compare Recursion Pharmaceuticals Inc (RXRX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Xylem, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.08 (market cap $1.53B), while Xylem, Inc. trades at $117.66 (market cap $28.67B). The key difference: Xylem, Inc. is far larger — about 18.7× Recursion Pharmaceuticals Inc's market cap, and Xylem, Inc. pays a 1.43% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | XYL | |
|---|---|---|
Market Cap | $1.53B | $28.67B |
Sector | Health | Industrials |
52-Week High | $6.79 | $152.95 |
52-Week Low | $2.84 | $106.34 |
Enterprise Value | $946.50M | $29.92B |
Dividend Yield | — | 1.43% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
